AI infrastructure demand remains the central growth catalyst. Dell has raised its fiscal 2027 (ending early 2027) revenue outlook to roughly $192 billion and now projects about $74 billion in AI-optimized server revenue, up from a prior $60 billion target. A record backlog provides revenue visibility. Dell exited its latest quarter with an AI server backlog of about $95 billion after booking roughly $60.9 billion in orders in a single quarter, signaling durable demand across enterprise, "neo-cloud," and sovereign customers.

GPRO is up roughly +36% to about $1.89 during regular trading, extending a multi-session surge. Move follows GoPro's $285 million merger with Starman Optical, pivoting the company into AI data-center optical transceivers and defense/aerospace.

DELL is the New York Stock Exchange ticker for Dell Technologies Inc., a global technology company headquartered in Round Rock, Texas. The company was founded by Michael Dell in 1984 and operates through two main segments: Client Solutions Group (PCs and peripherals) and Infrastructure Solutions Group (servers, storage, and networking).

PATH fell -17.18% during Thursday's regular session, sliding from a prior close of $18.22 to about $15.09, extending an overnight sell-off after Q2 FY2027 results. The decline came despite an earnings beat: revenue rose +13% to $410.3M, topping estimates, and full-year guidance was raised.

LULU is down roughly -17.19% to about $100.84, extending a selloff that began in Thursday's after-hours session following Q2 FY2026 results. Primary catalyst: the company issued its second full-year guidance cut, lowering FY2026 revenue to a 5–7% decline (prior flat to -1%) and EPS to $9.48–$9.73 from $10.95–$11.15.

GWRE is trading down -18.35% (to about $165.64) from its prior close of $202.86, extending a sharp slide that began in after-hours trading following its Sept. 3 earnings release. The drop was driven by fiscal Q4 FY2026 results that beat expectations (adjusted EPS $0.99 vs. $0.93; revenue $411.1M vs. ~$402.6M) but delivered disappointing forward guidance.

FICO is down -19.61% to roughly $899.50 during regular trading hours, extending a multi-session slide. Primary catalyst: FHFA Director Bill Pulte directed Fannie Mae and Freddie Mac to let all lenders use VantageScore, declaring "FICO has enjoyed a monopoly. No more."

PLTU surged approximately +111% over the last 30 days, reflecting its 2x daily leveraged exposure to Palantir Technologies. The fund also advanced roughly +43% over the trailing three months, recovering sharply from a late-June low.

MSTU , the T-Rex 2X Long MSTR Daily Target ETF, seeks 2x (200%) daily leveraged exposure to Strategy Inc. (MSTR) , the corporate bitcoin treasury company formerly known as MicroStrategy. The fund gained roughly 70% over the trailing 30 days as bitcoin rallied above $80,000 and MSTR shares rebounded sharply.

LABU advanced approximately +36% over the trailing 30-day window, reflecting a sharp rally in the underlying S&P Biotechnology Select Industry Index amplified by the fund's 3x daily leverage. The ETF also posted a strong quarter, climbing roughly +85% as biotechnology re-emerged as a leadership sector within U.S. equities.

CONL, a 2x daily-leveraged fund tied to Coinbase (COIN), surged roughly 31% over the last 30 days, amplifying an approximately 18% gain in its single underlying holding. Over the trailing quarter, CONL is down about 13% even though COIN is essentially flat, illustrating the volatility decay built into daily-reset leveraged products.

URNJ has climbed roughly 27% over the trailing 30 days, rebounding from a late-July low near $20.88 to approximately $27.96. The trailing quarter has been more volatile than the headline move suggests, with the fund roughly flat after a sharp mid-summer drawdown and recovery.

Late-stage pipeline readouts — including fianlimab in first-line melanoma and complement-inhibitor data in geographic atrophy and PNH (paroxysmal nocturnal hemoglobinuria, a rare blood disorder) — are expected through 2026 and could broaden Regeneron's commercial base. Dupixent and Eylea HD remain the core growth engines, with label expansions and a prospective Eylea HD prefilled syringe approval seen as near-term demand drivers.

The central question is whether Gelteq Limited (GELS) can climb back to the $1.00 level, a psychologically and regulatory significant milestone for this Nasdaq-listed micro-cap. The strongest bullish arguments are the company's early-stage revenue growth, its gel-delivery technology, and its stated path toward regulatory milestones and profitability.

The selected price target is $30 , roughly 55% above GDXD's recent trading level near $19. The strongest bullish factor is a meaningful pullback in gold mining equities, which would amplify inversely across GDXD's -3x daily leverage.

The $35 level is a widely watched ETF price target for MSFX, implying roughly 30% upside from recent trading levels. MSFX is a leveraged single-stock ETF designed to return 200% of Microsoft's (MSFT) daily move , magnifying both gains and losses.

The selected price target is $40 , roughly 27% above the latest closing price near $31.56. The strongest bullish factors include a newly reunited Del Monte brand, a value-added acquisition, and a six-year dividend growth streak.

The SPDR S&P 500 ETF Trust (SPY) is a passively managed exchange-traded fund (ETF) that tracks the S&P 500 Index of roughly 500 of the largest U.S. companies. Information Technology dominates the portfolio at roughly 37% of assets, led by Nvidia , Apple , and Microsoft .

Digital and on-site momentum: Fastenal's sales through its FMI (Fastenal Managed Inventory) technology and digital channels now account for a substantial and rising share of revenue, a key driver of medium-term growth. Upcoming catalyst: Third-quarter 2026 results, expected in mid-October, will test whether double-digit daily sales growth and margin expansion can be sustained.

The central question is whether NeuroPace (NPCE) can reach a $20 stock price target , a level aligned with the Wall Street consensus and roughly 35% above recent trading levels. Bullish support comes from strong revenue growth, a growing prescriber base, FDA-approved AI tools, and a potential expansion into idiopathic generalized epilepsy (IGE).